 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12345678910111213...208209» |
- || HRS7415 / Jiangsu Hengrui Pharma
Trial completion: A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Jul 2, 2026
P1, N=38, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Completed
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Trial completion: SHR-A1811-I-102: A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors (clinicaltrials.gov) - Jul 2, 2026
P1, N=101, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Completed Active, not recruiting --> Completed
- || AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
Trial completion: Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride (clinicaltrials.gov) - Jul 2, 2026
P1, N=36, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
Trial initiation date: The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia (clinicaltrials.gov) - Jul 2, 2026
P2, N=380, , Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || SHR-4394 / Jiangsu Hengrui Pharma
Trial initiation date: A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer (clinicaltrials.gov) - Jul 2, 2026
P1/2, N=100, , Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||||||| Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P3 trial: A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 1, 2026
P3, N=1000, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: ED90 of Tegileridine Combined With Propofol For Painless Gastroscopy (clinicaltrials.gov) - Jul 1, 2026
P4, N=108, Not yet recruiting, Sponsor: Shiyou Wei
- | retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
New P3 trial: Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases (clinicaltrials.gov) - Jun 30, 2026
P3, N=332, Not yet recruiting, Sponsor: Peking University
- ||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment closed: SHR-A1811-305: A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy (clinicaltrials.gov) - Jun 30, 2026
P3, N=1615, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| HRS-4508 / Jiangsu Hengrui Pharma
Enrollment open: A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor (clinicaltrials.gov) - Jun 29, 2026
P1/2, N=120, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Lorbrena (lorlatinib) / Pfizer, Rubraca (rucaparib) / Pharma& Schweiz
New P4 trial: Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed (clinicaltrials.gov) - Jun 29, 2026
P4, N=29, Not yet recruiting, Sponsor: Hunan Cancer Hospital
- SHR-1819 / Jiangsu Hengrui Pharma
Efficacy and Safety of SHR-1819 in Adult Patients with Prurigo Nodularis:Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial (The Results of the Phase II Trial) (Hall N) - Jun 28, 2026 - Abstract #EADV2026EADV_754;
- | Retrospective data, Review, Journal: Efficacy of immune-based combinations across treatment lines in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. (Pubmed Central) - Jun 27, 2026
For OS, ICI-anti-angiogenic combinations ranked highest, notably sintilimab plus IBI305 (HR = 0.57 vs. sorafenib; SUCRA = 0.94) and camrelizumab plus rivoceranib (HR = 0.62 vs. sorafenib; SUCRA = 0.89)...Regarding safety, ICI monotherapy/dual-blockade (e.g., pembrolizumab, nivolumab + ipilimumab) demonstrated better tolerability, whereas TKI-based combinations significantly increased Grade ?3 TRAE rates...These findings support a tailored continuum of care, guiding optimal sequencing based on pharmacological efficacy and safety profiles. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261296427, identifier CRD420261296427.
- | Journal: Case Report: Fatal pneumonitis caused by Camrelizumab and Erlotinib in a patient with metastatic pancreatic cancer. (Pubmed Central) - Jun 27, 2026
This case demonstrates that the combination of immunotherapy and Erlotinib may not constitute a safe therapeutic strategy for patients with advanced pancreatic cancer, as it can lead to severe pneumonitis. Significant caution should also be exercised when administering Erlotinib to patients who have recently undergone immune checkpoint inhibitor therapy.
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer (clinicaltrials.gov) - Jun 26, 2026
P2, N=70, Recruiting, Sponsor: Peking Union Medical College Hospital
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
CDK4/6 inhibitors + ET in HR+/HER2- Breast Cancer: A Network Meta-analysis (Poster Session Venue | Kyoto International Conference Center, 1st Floor Event Hall, New Hall; In-Person) - Jun 26, 2026 - Abstract #JBCS2026JBCS_1593;
All CDK4/6 inhibitors significantly improve outcomes, but Ribociclib + ET offers the greatest overall survival benefit. While Dalpiciclib and Abemaciclib provide superior PFS, they are associated with higher rates of neutropenia and diarrhoea.
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, Avastin (bevacizumab) / Roche
New P3 trial: TRIBE: An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC (clinicaltrials.gov) - Jun 25, 2026
P3, N=140, Not yet recruiting, Sponsor: Fudan University
- || M9466 / EMD Serono
Enrollment change: M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) (clinicaltrials.gov) - Jun 24, 2026
P1, N=60, Active, not recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
While Dalpiciclib and Abemaciclib provide superior PFS, they are associated with higher rates of neutropenia and diarrhoea. N=141 --> 60
- | retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
New P2 trial: Short-course Radiotherapy Combined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-arm, Phase II Clinical Study (clinicaltrials.gov) - Jun 23, 2026
P2, N=44, Active, not recruiting, Sponsor: Harbin Medical University
- | Tevimbra (tislelizumab-jsgr) / BeOne Medicines, zeprumetostat (SHR-2554) / Treeline Biosci
Enrollment open: EpiRev-NKT: Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma (clinicaltrials.gov) - Jun 18, 2026
P1/2, N=107, Recruiting, Sponsor: Rong Tao
N=141 --> 60 Not yet recruiting --> Recruiting
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
Trial initiation date, Head-to-Head: Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery (clinicaltrials.gov) - Jun 17, 2026
P4, N=171, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
Not yet recruiting --> Recruiting Initiation date: Jan 2026 --> Jul 2026
- | New P2/3 trial, Checkpoint inhibition: ESCC-PT: Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer (clinicaltrials.gov) - Jun 17, 2026
P2/3, N=90, Not yet recruiting, Sponsor: Peking University Cancer Hospital & Institute
- |||||| rivocibart (SHR-1918) / Jiangsu Hengrui Pharma
Enrollment open: A Study of SHR-1918 In Participants With Hypertriglyceridemia (clinicaltrials.gov) - Jun 17, 2026
P3, N=360, Recruiting, Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
Initiation date: Jan 2026 --> Jul 2026 Not yet recruiting --> Recruiting
- |||| rivocibart (SHR-1918) / Jiangsu Hengrui Pharma
Enrollment open: A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors (clinicaltrials.gov) - Jun 16, 2026
P2/3, N=126, Recruiting, Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
New P2 trial: Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer (clinicaltrials.gov) - Jun 16, 2026
P2, N=124, Recruiting, Sponsor: The First Affiliated Hospital of Soochow University
- | New trial, Real-world evidence: A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions (clinicaltrials.gov) - Jun 12, 2026
P=N/A, N=1000, Active, not recruiting, Sponsor: Harbin Medical University
- | New trial: The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study (clinicaltrials.gov) - Jun 10, 2026
P=N/A, N=715, Completed, Sponsor: Tongji Hospital
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, AiRuiKa (camrelizumab) / Elevar Therapeutics
New P2 trial: Multi-Omics-Based Phase ? Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma (clinicaltrials.gov) - Jun 10, 2026
P2, N=44, Not yet recruiting, Sponsor: Sheng Tai
- |||| GSK6582701 / GSK
New P2 trial: A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jun 10, 2026
P2, N=90, Not yet recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
- | Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: TASPER: Tegileridine vs Sufentanil for Postoperative Pain Management and Gastrointestinal Recovery After Major Laparoscopic Abdominal Surgery (clinicaltrials.gov) - Jun 10, 2026
P4, N=84, Not yet recruiting, Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer (clinicaltrials.gov) - Jun 10, 2026
P2, N=170, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer (clinicaltrials.gov) - Jun 9, 2026
P2, N=182, Recruiting, Sponsor: Hebei Medical University Fourth Hospital
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New P2 trial: Ivarmacitinib for Refractory Behcet's Syndrome (clinicaltrials.gov) - Jun 9, 2026
P2, N=30, Not yet recruiting, Sponsor: Liu Tian
- Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
Enrollment open: Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction (clinicaltrials.gov) - Jun 9, 2026
P4, N=48, Recruiting, Sponsor: University of Alabama at Birmingham
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
New P2 trial: Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor (clinicaltrials.gov) - Jun 8, 2026
P2, N=15, Not yet recruiting, Sponsor: Haihua Yuan
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Enrollment change, Trial withdrawal: Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia (clinicaltrials.gov) - Jun 8, 2026
P2/3, N=0, Withdrawn, Sponsor: Peking Union Medical College Hospital
Not yet recruiting --> Recruiting N=40 --> 0 | Not yet recruiting --> Withdrawn
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
New P2 trial: Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer (clinicaltrials.gov) - Jun 6, 2026
P2, N=100, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- || AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
Trial completion, Enrollment change: Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride (clinicaltrials.gov) - Jun 6, 2026
P1, N=36, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=40 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Completed | N=18 --> 36
- |||||| HRS-7535 / Kailera Therapeutics
Enrollment open: Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity (clinicaltrials.gov) - Jun 5, 2026
P3, N=648, Recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
Not yet recruiting --> Completed | N=18 --> 36 Not yet recruiting --> Recruiting
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, Idafang (ivonescimab) / Summit Therapeutics
New P2 trial: Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities (clinicaltrials.gov) - Jun 5, 2026
P2, N=30, Not yet recruiting, Sponsor: Sun Yat-sen University
- || HRS-3738 / Jiangsu Hengrui Pharma
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma (clinicaltrials.gov) - Jun 5, 2026
P1, N=74, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=198 --> 74 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Oct 2024 --> Dec 2026
- ||||||| remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Trial completion: A Trial of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent Patients (clinicaltrials.gov) - Jun 4, 2026
P2/3, N=249, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting | N=198 --> 74 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Oct 2024 --> Dec 2026 Recruiting --> Completed
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer (clinicaltrials.gov) - Jun 3, 2026
P2, N=58, Not yet recruiting, Sponsor: Harbin Medical University
- || Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
Trial initiation date: CSAGCD: Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye (clinicaltrials.gov) - Jun 3, 2026
P4, N=60, Not yet recruiting, Sponsor: Baylor College of Medicine
Recruiting --> Completed Initiation date: Apr 2026 --> Sep 2026
- | retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
New P2 trial: SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 2, 2026
P2, N=84, Not yet recruiting, Sponsor: Fudan University
- | New P2 trial: TAYLOR-002: Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer (clinicaltrials.gov) - Jun 2, 2026
P2, N=45, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- | zeprumetostat (SHR-2554) / Treeline Biosci, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P1/2 trial: Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma (clinicaltrials.gov) - May 30, 2026
P1/2, N=40, Not yet recruiting, Sponsor: Sun Yat-sen University
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Epidaza (chidamide) / Chipscreen
Trial completion, Trial completion date, Trial primary completion date: MA-BC-II-047: Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase ?b Study (clinicaltrials.gov) - May 30, 2026
P1, N=22, Completed, Sponsor: Beijing 302 Hospital
Initiation date: Apr 2026 --> Sep 2026 Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2024 --> Dec 2025 | Not yet recruiting --> Completed
- GSK6582701 / GSK
Safety and Efficacy of inhaled HRS-9821 suspension, a novel dual PDE3/4 Inhibitor: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study in COPD Patients (PS-13) - May 30, 2026 - Abstract #ERS2026ERS_551;
- GSK6582701 / GSK
Safety, Tolerability and Pharmacokinetics of innovative, dual PDE3 and PDE4 inhibitor HRS-9821 suspension for inhalation in healthy participants (PS-13) - May 30, 2026 - Abstract #ERS2026ERS_539;